The Latest Cardiac and Vascular News
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late […]
Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System Westport, CT, Nov. 08, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the […]
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara’s new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage […]
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Cardiologs will further strengthen Philips’ cardiac monitoring and […]
Results Presented at Transcatheter Cardiovascular Therapeutics 2021 ORLANDO, Fla.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an analysis of multiple studies that showed positive outcomes with its investigational AccuCinch® Ventricular Restoration System. The results were presented during a Featured Clinical Research […]
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems’ Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems’ Board consists […]
– KARDIA-2 will Evaluate Efficacy and Safety of Zilebesiran when Used in Combination with Conventional Antihypertensive Medications – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as […]
– In a new sub-analysis of the landmark EMPEROR-Preserved® Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 – Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m2 1 INGELHEIM, […]
AI-powered algorithms are proven to accurately predict the likelihood a patient with moderate AS has progressed to severe AS. ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc. presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 conference held November 4-6. The presentation showcased the proven accuracy and results of artificial intelligence (AI) […]
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted and concluded that DiaMedica “may proceed” with the proposed clinical investigation using its amended protocol adding stroke […]
